Ampio | search
Click here to view Ampio news from 60+ newspapers.
Bookmark or Share- Ampio Pharmaceuticals - Ampio PharmaceuticalsDear Ampio Stockholders: The Plan of Dissolution as recommended by our board was approved by stockholders at our special meeting on August 15, 2024. Accordingly, Ampio is dissolved as of August 16, 2024 ( Certificate of Dissolution ) and we have published a Notice of Dissolution .
- Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services ...The OA-201 development program is seeking to advance Ampio’s unique and proprietary small molecule formulation to take forward through pain and chondroprotection pre-clinical studies and the next phases of drug development.
- Ampio Provides Update on Results from Pre-IND Enabling StudiesENGLEWOOD, Colo., February 14, 2024 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre ...
- Ampio Provides Litigation Update Reports Settlement in Principle of ...ENGLEWOOD, Colo., January 11, 2024 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has reached settlements in principle in the pending ...
- Ampio Letter to Stockholders - Ampio ... - Ampio PharmaceuticalsENGLEWOOD, Colo., August 3, 2022 — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
More
